The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Tarsus Pharmaceuticals Inc shares valued at $495,089 were sold by Azamian Bobak R. on Dec 24 ’25. At $82.51 per share, Azamian Bobak R. sold 6,000 shares. The insider’s holdings dropped to 857,991 shares worth approximately $70.25 million following the completion of this transaction.
Also, BOBAK AZAMIAN purchased 6,000 shares, netting a total of over 495,089 in proceeds.
Before that, Whitfield Dianne C. had sold 7,397 shares from its account. In a trade valued at $592,500, the Chief Human Resources Officer traded Tarsus Pharmaceuticals Inc shares for $80.10 each. Upon closing the transaction, the insider’s holdings decreased to 7,397 shares, worth approximately $3.19 million.
As published in their initiating research note from Barclays on December 09, 2025, Tarsus Pharmaceuticals Inc [TARS] has been an Overweight and the price target has been revised to $100. Analysts at Mizuho started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid November.
Analyzing TARS Stock Performance
On last trading session, Tarsus Pharmaceuticals Inc [NASDAQ: TARS] plunged -0.55% to $81.88. The stock’s lowest price that day was $81.86, but it reached a high of $83.94 in the same session. During the last five days, there has been a drop of approximately -0.30%. Over the course of the year, Tarsus Pharmaceuticals Inc shares have jumped approximately 48.87%. Shares of the company reached a 52-week high of $85.25 on 12/09/25 and a 52-week low of $38.51 on 08/01/25.
Support And Resistance Levels for Tarsus Pharmaceuticals Inc (TARS)
According to the 24-hour chart, there is a support level at 81.18, which, if violated, would cause prices to drop to 80.48. In the upper region, resistance lies at 83.26. The next price resistance is at 84.64. RSI (Relative Strength Index) is 58.61 on the 14-day chart, showing neutral technical sentiment.
Is Tarsus Pharmaceuticals Inc subject to short interest?
Stocks of Tarsus Pharmaceuticals Inc saw a sharp steep in short interest on 2025-12-15 dropping by -0.36 million shares to 6.81 million. Data from Yahoo Finance shows that the short interest on 2025-11-14 was 7.17 million shares. A decline of -5.28% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 15.41 of the overall float, the days-to-cover ratio (short ratio) decline to 15.41.
Which companies own the most shares of Tarsus Pharmaceuticals Inc (TARS)?
In terms of Tarsus Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 94 in the next 12 months, up nearly 14.17% from the previous closing price of $82.33. Analysts anticipate Tarsus Pharmaceuticals Inc stock to reach 100 by 2026, with the lowest price target being 51. In spite of this, 4 analysts ranked Tarsus Pharmaceuticals Inc stock as Buy at the end of 2026. On November 20, 2023, Goldman assigned a price target of “a Neutral” to the stock and initiated coverage with a $19.
